Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Gabriella Honeth"'
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
CDK4/6 inhibitors in combination with endocrine therapy has shown efficacy in ER + breast cancer patients but resistance can occur. Here, the authors demonstrate that co-targeting CDK4/6 and AKT with endocrine therapy prevents acquired resistance and
Externí odkaz:
https://doaj.org/article/73e69d21bd364412a70101afb76ad7da
Autor:
Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch, Gabriella Honeth
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Abstract Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need
Externí odkaz:
https://doaj.org/article/7cbcb174cf144b08807aab383e525e6b
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/df7e78eab9c643b4bcc917eea8a3ff30
Autor:
Maria Bååth, Jenny-Maria Jönsson, Sofia Westbom Fremer, Laura Martín de la Fuente, Lena Tran, Susanne Malander, Päivi Kannisto, Anna Måsbäck, Gabriella Honeth, Ingrid Hedenfalk
Publikováno v:
Genes, Vol 12, Iss 5, p 742 (2021)
Overexpression of the receptor tyrosine kinase MET has been linked to poor survival in several cancer types, and MET has been suggested to interact with stem cell networks. In vitro studies have further suggested a possible benefit of a combined trea
Externí odkaz:
https://doaj.org/article/e53960c1077c41ceb8806c699691facf
Autor:
Gabriella Honeth, Tommaso Schiavinotto, Federico Vaggi, Rebecca Marlow, Tokuwa Kanno, Ireneusz Shinomiya, Sara Lombardi, Bharath Buchupalli, Rosalind Graham, Patrycja Gazinska, Vernie Ramalingam, Joy Burchell, Anand D. Purushotham, Sarah E. Pinder, Attila Csikasz-Nagy, Gabriela Dontu
Publikováno v:
Stem Cell Reports, Vol 4, Iss 4, Pp 699-711 (2015)
Characterization of normal breast stem cells is important for understanding their role in breast development and in breast cancer. However, the identity of these cells is a subject of controversy and their localization in the breast epithelium is not
Externí odkaz:
https://doaj.org/article/bbeca0c301214be8a16770bbe217e578
Autor:
Sara Lombardi, Gabriella Honeth, Christophe Ginestier, Ireneusz Shinomiya, Rebecca Marlow, Bharath Buchupalli, Patrycja Gazinska, John Brown, Steven Catchpole, Suling Liu, Ariel Barkan, Max Wicha, Anand Purushotham, Joy Burchell, Sarah Pinder, Gabriela Dontu
Publikováno v:
Stem Cell Reports, Vol 2, Iss 6, Pp 780-793 (2014)
Using in vitro and in vivo experimental systems and in situ analysis, we show that growth hormone (GH) is secreted locally by normal human mammary epithelial cells upon progesterone stimulation. GH increases proliferation of a subset of cells that ex
Externí odkaz:
https://doaj.org/article/6263ea4d7c0f48a2aa9ad775f769d4d6
Autor:
Gabriela Dontu, Andrew Tutt, Anand Purushotham, Pranela Rameshwar, Agamemnon Grigoriadis, Dominique Bonnet, Katie Foster, Bharath Buchupalli, Veronica Mariotti, Aikaterini Pipili, Sonya Hessey, Massimiliano Cariati, Sara Lombardi, Gabriella Honeth, Rebecca Marlow
PDF file - 1575K, Supplementary Figure 1. Set-up of the two bone marrow metastatic niche models - Inhibitory Niche (Bone Marrow Cell lines, BMCL) and Supportive Niche (Human Bone Marrow Stromal Cells, BMSC). Supplementary Figure 2. Set-up of bone mar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d43c3cca7c79be4052806a83d82730
https://doi.org/10.1158/0008-5472.22397258
https://doi.org/10.1158/0008-5472.22397258
Autor:
Johan Vallon-Christersson, Anna Ebbesson, Eugenia Cordero, Sowndarya Muthukumar, Roberto Munita, Giulia Beneventi, Karin Jirström, Kristina Lövgren, Terese Jönsson, Magdalena Madej, Ana Bosch, Maciej Cieśla, Álvaro Sejas Martinez, Mikkel Morsing, Björn Nodin, Ingrid Hedenfalk, Danny Incarnato, Cristian Bellodi, Johan Staaf, Phuong Cao Thi Ngoc, Kristian Pietras, Gabriella Honeth
Publikováno v:
Molecular Cell, 81(7):j.molcel.2021.01.034, 1453-1468. CELL PRESS
Splicing is a central RNA-based process commonly altered in human cancers; however, how spliceosomal components are co-opted during tumorigenesis remains poorly defined. Here we unravel the core splice factor SF3A3 at the nexus of a translation-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9df2847fe43c27cd85566e4b0e55bf3a
https://research.rug.nl/en/publications/1055686c-7a3e-48d9-8536-000cc4379b5b
https://research.rug.nl/en/publications/1055686c-7a3e-48d9-8536-000cc4379b5b
Autor:
Henrik J. Ditzel, Lukas Beumers, Anna Ebbesson, Sidse Ehmsen, Katja Harbst, Alejandro Pérez-Fidalgo, Åke Borg, Kamila Kaminska, Anna Ehinger, Ingrid Hedenfalk, Ana Bosch, Johan Staaf, Gabriella Honeth, Srinivas Veerla, Nina Akrap, Carla Maria Lourenco Alves, Signe Borgquist
Publikováno v:
Kaminska, K, Akrap, N, Staaf, J, Alves, C L, Ehinger, A, Ebbesson, A, Hedenfalk, I, Beumers, L, Veerla, S, Harbst, K, Ehmsen, S, Borgquist, S, Borg, Å, Pérez-Fidalgo, A, Ditzel, H J, Bosch, A & Honeth, G 2021, ' Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer ', Breast Cancer Research, vol. 23, no. 1, 26 . https://doi.org/10.1186/s13058-021-01402-1
Breast Cancer Research : BCR
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Breast Cancer Research : BCR
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need is mainly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::609cd3b141c557d10545f07257a75a91
https://pure.au.dk/portal/da/publications/distinct-mechanisms-of-resistance-to-fulvestrant-treatment-dictate-level-of-er-independence-and-selective-response-to-cdk-inhibitors-in-metastatic-breast-cancer(76ba9d6a-cca3-4b66-8afa-dbead4115cce).html
https://pure.au.dk/portal/da/publications/distinct-mechanisms-of-resistance-to-fulvestrant-treatment-dictate-level-of-er-independence-and-selective-response-to-cdk-inhibitors-in-metastatic-breast-cancer(76ba9d6a-cca3-4b66-8afa-dbead4115cce).html
Autor:
Ana Bosch, Mikkel G. Terp, Henrik J. Ditzel, Monique F. Hundebøl, Neil Portman, Lene E. Johansen, Kamila Kaminska, Gabriella Honeth, Carla Maria Lourenco Alves, Martin Bak, Odd L. Gammelgaard, Elgene Lim, Martina Tuttolomondo, Sidse Ehmsen
Publikováno v:
Nature Communications
Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ', Nature Communications, vol. 12, 5112 . https://doi.org/10.1038/s41467-021-25422-9
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ', Nature Communications, vol. 12, 5112 . https://doi.org/10.1038/s41467-021-25422-9
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most patients will eventually experience disease progression on this combination, underscoring t